HOUSTON--(BUSINESS WIRE)--CorInnova Inc., an emerging medical device company developing breakthrough technology for the treatment of Heart Failure, announced today that it has won First Prize in the “RESI (Redefining Early Stage Investments) San Francisco 2018” investment competition for early-stage life science companies.
“We are excited that early-stage investors instantly grasp the dramatic value proposition that EpicHeart represents: a potentially transformational paradigm for treating Heart Failure,” said William Altman, CEO of CorInnova. “Presently, less than two percent of end-stage Heart Failure patients are treated by transplant or by LVADs. Only about eight percent are considered eligible for LVADs due to the invasive surgery required for implantation.
“EpicHeart will potentially quadruple the number of patients who might benefit from a minimally invasive heart assist device,” added Altman. “Like the introduction of pacemakers and ICDs to patients with electrical abnormalities affecting heart function, EpicHeart has the potential to transform the treatment of heart failure patients worldwide.”
Click here to see how CorInnova’s EpicHeart™ soft robotic, non-blood-contacting heart assist device is delivered minimally invasively to support heart function.
The RESI Innovation Challenge prize is the latest in a string of recent awards won by CorInnova, including Rice Alliance Most Promising Texas Life Science Company; the US-China Innovation Alliance InnoSTARS prize awarded in Kunming, China; the NCC-PDI Pediatric Innovation Prize; and, the TCT 2018 Shark Tank Finalist award.
About CorInnova Inc.
CorInnova has been supported by a group
of private investors, a major investment from the UK-based Wellcome
Trust (Translation Fund Award No. 104613); federal institutions
including the NIH, National Heart Lung Blood Institute (NHLBI), and
National Science Foundation (NSF); and the Texas Emerging Technology
Fund.
CAUTION: EpicHeart™ is not approved for human use at this time.
